<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Error Analysis - Top Issuers Summary</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            line-height: 1.5;
            color: #000;
            background: white;
            padding: 20px;
        }
        
        h1 {
            font-size: 24px;
            margin-bottom: 20px;
        }
        
        h2 {
            font-size: 20px;
            font-weight: bold;
            margin: 20px 0 10px 0;
        }
        
        h3 {
            font-size: 16px;
            font-weight: bold;
            margin: 15px 0 5px 0;
        }
        
        ul {
            margin: 10px 0;
            padding-left: 20px;
        }
        
        li {
            margin: 5px 0;
        }
        
        p {
            margin: 5px 0;
        }
    </style>
</head>
<body>
    <h1>Error Analysis - Top Issuers Summary</h1>
    

    <h2>VIRPAX PHARMACEUTICALS, INC.</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: BN</li>
        <li>Management Recommendations: F</li>
        <li>Total Proposals: 7</li>
        <li>Range of Approval Rate of Failed Proposals: 33.2%-37.5%</li>
        <li>Rejected Count: 7</li>
        <li>Approved Count: 0</li>
    </ul>
    <h3>Record Dates</h3>
    <p>11/21/2024</p>
    <h3>Job Numbers</h3>
    <p>Z88995</p>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>Services: BN</li>
        <li>Management recommendations: F</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Board of Directors (5)</li>
        <li>Category Summary: Shareholder Rights (1)</li>
        <li>Category Summary: Corporate Actions (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>Election of Director to hold office until our Annual Meeting of Stockholders to be held in 2025 or their respective successor is duly elected and qualified: Esha Randhawa <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 260668 (6.1%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 438010 (10.3%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 8983 (0.2%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 3554185 (83.4%)</span>]</span></li>
        <li>Election of Director to hold office until our Annual Meeting of Stockholders to be held in 2025 or their respective successor is duly elected and qualified: Jatinder Dhaliwal <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 260085 (6.1%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 438593 (10.3%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 8983 (0.2%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 3554185 (83.4%)</span>]</span></li>
        <li>Election of Director to hold office until our Annual Meeting of Stockholders to be held in 2025 or their respective successor is duly elected and qualified: Jaydriane Panis <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 222408 (5.2%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 437980 (10.3%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 47273 (1.1%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 3554185 (83.4%)</span>]</span></li>
        <li>Election of Director to hold office until our Annual Meeting of Stockholders to be held in 2025 or their respective successor is duly elected and qualified: Judy Su <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 262348 (6.2%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 436330 (10.2%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 8983 (0.2%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 3554185 (83.4%)</span>]</span></li>
        <li>Election of Director to hold office until our Annual Meeting of Stockholders to be held in 2025 or their respective successor is duly elected and qualified: Katharyn Field <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 260827 (6.1%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 437854 (10.3%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 8980 (0.2%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 3554185 (83.4%)</span>]</span></li>
        <li>To approve an adjournment of the 2025 Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes in favor of the Reverse Stock Split Proposal and/or the Director Proposal (the &quot;Adjournment Proposal&quot; or &quot;Proposal 3&quot;). <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 260421 (6.1%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 441909 (10.3%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 5331 (0.1%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 3570226 (83.5%)</span>]</span></li>
        <li>To approve an amendment to the Company&#x27;s Amended and Restated Certificate of Incorporation, in substantially the form attached to the proxy statement as Annex A, to, at the discretion of the BOD of the Company, effect a reverse stock split with respect to the Company&#x27;s issued and outstanding common stock, par value $0.00001 per share, including stock held by the Company as treasury shares, at a ra... <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 233799 (5.5%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 469569 (11.0%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 4293 (0.1%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 3554185 (83.4%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>1847 HOLDINGS LLC</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: BD</li>
        <li>Management Recommendations: F</li>
        <li>Total Proposals: 5</li>
        <li>Range of Approval Rate of Failed Proposals: 12.6%-24.3%</li>
        <li>Rejected Count: 5</li>
        <li>Approved Count: 0</li>
    </ul>
    <h3>Record Dates</h3>
    <p>1/22/2025</p>
    <h3>Job Numbers</h3>
    <p>S06269</p>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>Services: BD</li>
        <li>Management recommendations: F</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Shareholder Equity (3)</li>
        <li>Category Summary: Corporate Structure (1)</li>
        <li>Category Summary: Shareholder Rights (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>Approval has been granted to issue all common shares related to the exercise of Pre-funded warrants, December Series A warrants, and December Series B warrants, all of which were issued on December 16, 2024. This approval encompasses shares issued due to adjustments in warrant terms, including voluntary price adjustments, modifications after a Share Combination Event, changes following the Reset D... <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 256252 (2.2%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 1198580 (10.5%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 22945 (0.2%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 9959721 (87.1%)</span>]</span></li>
        <li>The proposal updates the terms of October Series A &amp; Series B warrants issued on October 30, 2024. For the Series A Warrants, both the exercise price and Floor Price are adjusted to $0.81, with an increase in the number of underlying common shares to maintain the overall exercise value. This adjustment is subject to modifications due to events like stock splits, combinations, &amp; recapitalizations. ... <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 354971 (3.1%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 1107492 (9.7%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 15315 (0.1%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 9959721 (87.1%)</span>]</span></li>
        <li>To approve Amendment No. 3 to the 1847 Holdings LLC 2023 Equity Incentive Plan to increase the share reserve to 5,000,000 common shares. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 206266 (1.8%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 1254706 (11.0%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 16805 (0.1%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 9959721 (87.1%)</span>]</span></li>
        <li>To approve Amendment No. 4 to the Second Amended and Restated Operating Agreement of the Company to increase the number of authorized common shares to 2,000,000,000 shares. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 184364 (1.6%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 1275072 (11.1%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 18341 (0.2%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 9959721 (87.1%)</span>]</span></li>
        <li>To approve the adjournment of the Special Meeting to a later date if necessary to solicit additional proxies if there are not sufficient votes to approve any of the foregoing proposals at the time of the Special Meeting, or any adjournment or postponement thereof. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 219600 (1.9%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 1237126 (10.8%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 21051 (0.2%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 9959721 (87.1%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>CYNGN INC.</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: BN</li>
        <li>Management Recommendations: F</li>
        <li>Total Proposals: 4</li>
        <li>Range of Approval Rate of Failed Proposals: 21.6%-42.5%</li>
        <li>Rejected Count: 4</li>
        <li>Approved Count: 0</li>
    </ul>
    <h3>Record Dates</h3>
    <p>12/2/2024</p>
    <h3>Job Numbers</h3>
    <p>S02870</p>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>Services: BN</li>
        <li>Management recommendations: F</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Corporate Structure (1)</li>
        <li>Category Summary: Shareholder Rights (1)</li>
        <li>Category Summary: Corporate Actions (1)</li>
        <li>Category Summary: Shareholder Equity (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>Approval of an amendment to the Company&#x27;s Certificate of Incorporation to increase the number of authorized common stock from 200,000,000 to 400,000,000 shares. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 60024 (3.8%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 125147 (7.9%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 1439 (0.1%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 1390924 (88.2%)</span>]</span></li>
        <li>Approval of, if necessary, the adjournment or postponement of the Special Meeting, to continue to solicit votes for Proposals 1, 2 and 3. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 39389 (2.5%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 143001 (9.1%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 4220 (0.3%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 1390924 (88.2%)</span>]</span></li>
        <li>Grant discretionary authority to our board of directors to (i) amend our certificate of incorporation to combine outstanding shares of our common stock into a lesser number of outstanding shares, or a &quot;reverse stock split,&quot; at a specific ratio within a range of one-for-five (1-for-5) to a maximum of a one-for-one hundred fifty (1-for-150) split, with the exact ratio to be determined by our board o... <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 48359 (3.1%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 137064 (8.7%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 1187 (0.1%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 1390924 (88.2%)</span>]</span></li>
        <li>To authorize, for purposes of complying with NASDAQ Listing Rule 5635(D), the issuance of the Warrants, shares of our common stock underlying the Warrants and certain provisions of the Warrants, issued in connection with an offering and sale of securities of the Company that was consummated on December 23, 2024. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 77202 (4.9%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 104669 (6.6%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 4739 (0.3%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 1390924 (88.2%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>WINDTREE THERAPEUTICS, INC.</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: BN</li>
        <li>Management Recommendations: F</li>
        <li>Total Proposals: 3</li>
        <li>Range of Approval Rate of Failed Proposals: 28.9%-33.3%</li>
        <li>Rejected Count: 3</li>
        <li>Approved Count: 0</li>
    </ul>
    <h3>Record Dates</h3>
    <p>12/20/2024</p>
    <h3>Job Numbers</h3>
    <p>S05496</p>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>Services: BN</li>
        <li>Management recommendations: F</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Shareholder Rights (1)</li>
        <li>Category Summary: Shareholder Equity (1)</li>
        <li>Category Summary: Compensation (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>To approve adjournment of the Special Meeting to the extent there are insufficient votes at the Special Meeting to approve Proposal 1 or Proposal 2 or to establish a quorum. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 451444 (6.7%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 905852 (13.4%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 107364 (1.6%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 5313575 (78.4%)</span>]</span></li>
        <li>To approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our outstanding shares of common stock, par value $0.001 per share by a ratio of any whole number between 1-for-5 and 1-for 50, the implementation and timing of which shall be subject to the discretion of the Board of Directors. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 408463 (6.0%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 996023 (14.7%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 60174 (0.9%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 5313575 (78.4%)</span>]</span></li>
        <li>To approve an amendment to our Amended and Restated Windtree Therapeutics, Inc. 2020 Equity Incentive Plan to increase the number of shares of common stock, par value $0.001 per share, authorized for issuance under such plan from 41,010 shares to 1,141,010 shares. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 404056 (6.0%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 991609 (14.6%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 68995 (1.0%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 5313575 (78.4%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>HEPION PHARMACEUTICALS, INC.</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: BN</li>
        <li>Management Recommendations: F</li>
        <li>Total Proposals: 10</li>
        <li>Range of Approval Rate of Failed Proposals: 37.2%-42.4%</li>
        <li>Rejected Count: 3</li>
        <li>Approved Count: 7</li>
    </ul>
    <h3>Record Dates</h3>
    <p>1/17/2025</p>
    <h3>Job Numbers</h3>
    <p>P25298</p>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>Services: BN</li>
        <li>Management recommendations: F</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Corporate Actions (1)</li>
        <li>Category Summary: Shareholder Equity (1)</li>
        <li>Category Summary: Compensation (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>Proposal to approve an amendment to the Company&#x27;s Certificate of Incorporation, as amended (the &quot;Certificate of Incorporation&quot;) to effect a reverse stock split of the Company&#x27;s common stock at a ratio of between 1-for-10 and 1-for-50, with such ratio to be determined at the sole discretion of the board of directors of the Company and with such Reverse Stock Split to be effected at such time and da... <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 549870 (11.7%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 746732 (15.9%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 40890 (0.9%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 3355177 (71.5%)</span>]</span></li>
        <li>Proposal to approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the full issuance of shares of common stock, par value $0.0001 per share, issuable by the Company upon exercise of the Series A Warrants and the Series B Warrants. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 547481 (11.7%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 753780 (16.1%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 36230 (0.8%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 3355177 (71.5%)</span>]</span></li>
        <li>Proposal to approve, on an advisory basis, the compensation of the Company&#x27;s named executive officers. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 482447 (10.3%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 813849 (17.3%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 41196 (0.9%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 3355177 (71.5%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>MOTORSPORT GAMES INC.</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: BN</li>
        <li>Management Recommendations: F</li>
        <li>Total Proposals: 6</li>
        <li>Range of Approval Rate of Failed Proposals: 6.7%-7.5%</li>
        <li>Rejected Count: 2</li>
        <li>Approved Count: 4</li>
    </ul>
    <h3>Record Dates</h3>
    <p>3/11/2025</p>
    <h3>Job Numbers</h3>
    <p>P28868</p>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>Services: BN</li>
        <li>Management recommendations: F</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Compensation (1)</li>
        <li>Category Summary: Shareholder Equity (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>Approval of an amendment to the Amended and Restated Motorsport Games Inc. 2021 Equity Incentive Plan to increase the number of shares of the Company&#x27;s Class A common stock available for awards thereunder by 200,000 shares. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 158333 (4.5%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 2213605 (63.4%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 171 (0.0%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 1119294 (32.1%)</span>]</span></li>
        <li>Approval of the exercise of warrants issued on July 29, 2024 to purchase up to an aggregate of 949,310 shares of Class A Common Stock under applicable rules and regulations of the Nasdaq Stock Market LLC. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 178065 (5.1%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 2193852 (62.8%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 192 (0.0%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 1119294 (32.1%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>AUDDIA INC</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: BN</li>
        <li>Management Recommendations: F</li>
        <li>Total Proposals: 14</li>
        <li>Range of Approval Rate of Failed Proposals: 44.7%-45.6%</li>
        <li>Rejected Count: 2</li>
        <li>Approved Count: 12</li>
    </ul>
    <h3>Record Dates</h3>
    <p>4/4/2025</p>
    <h3>Job Numbers</h3>
    <p>S12670</p>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>Services: BN</li>
        <li>Management recommendations: F</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Corporate Structure (2)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>Proposal to grant discretionary authority to our board of directors to amend our Certificate of Incorporation to effect the reverse stock split. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 9028 (2.6%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 11159 (3.2%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 14 (0.0%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 333459 (94.3%)</span>]</span></li>
        <li>Proposal to grant discretionary authority to our board of directors to amend our Certificate of Incorporation to increase the number of our authorized shares of common stock from 100,000,000 shares to 250,000,000 shares. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 9208 (2.6%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 10969 (3.1%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 24 (0.0%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 333459 (94.3%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>LIVEPERSON, INC.</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: DR</li>
        <li>Management Recommendations: F</li>
        <li>Total Proposals: 7</li>
        <li>Range of Approval Rate of Failed Proposals: 42.8%</li>
        <li>Rejected Count: 1</li>
        <li>Approved Count: 6</li>
    </ul>
    <h3>Record Dates</h3>
    <p>11/5/2024</p>
    <h3>Job Numbers</h3>
    <p>Z88877</p>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>Services: DR</li>
        <li>Management recommendations: F</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Corporate Governance (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>Approval of the Company&#x27;s Tax Benefits Preservation Plan so that it may remain in effect through January 21, 2027 unless earlier terminated by the Company&#x27;s Board of Directors. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 23084559 (16.6%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 30842579 (22.1%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 624594 (0.4%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 84711912 (60.8%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>FOXO TECHNOLOGIES INC.</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: BN</li>
        <li>Management Recommendations: F</li>
        <li>Total Proposals: 9</li>
        <li>Range of Approval Rate of Failed Proposals: 45.2%</li>
        <li>Rejected Count: 1</li>
        <li>Approved Count: 8</li>
    </ul>
    <h3>Record Dates</h3>
    <p>11/15/2024</p>
    <h3>Job Numbers</h3>
    <p>S01913</p>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>Services: BN</li>
        <li>Management recommendations: F</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Corporate Actions (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>To approve and adopt a proposal to amend our Third Amended and Restated Certificate of Incorporation, to effect a reverse stock split of our issued and outstanding Class A common stock, par value $0.0001 per share before 09/30/2025, at a ratio ranging from one-for-five (1:5) to one-for-one hundred (1:100) (&quot;Reverse Split&quot;) with the exact ratio within such range to be determined at the sole discret... <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 173611 (1.8%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 210750 (2.2%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 1702 (0.0%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 9204583 (96.0%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>PREDICTIVE ONCOLOGY INC.</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: BN</li>
        <li>Management Recommendations: F</li>
        <li>Total Proposals: 5</li>
        <li>Range of Approval Rate of Failed Proposals: 47.2%</li>
        <li>Rejected Count: 1</li>
        <li>Approved Count: 4</li>
    </ul>
    <h3>Record Dates</h3>
    <p>11/27/2024</p>
    <h3>Job Numbers</h3>
    <p>P21329</p>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>Services: BN</li>
        <li>Management recommendations: F</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Compensation (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>Vote on a non-binding advisory resolution to approve compensation of the Company&#x27;s executive officers. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 867246 (8.0%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 968583 (8.9%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 68177 (0.6%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 8960701 (82.5%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>CATHETER PRECISION, INC.</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: BN</li>
        <li>Management Recommendations: F</li>
        <li>Total Proposals: 5</li>
        <li>Range of Approval Rate of Failed Proposals: 49.2%</li>
        <li>Rejected Count: 1</li>
        <li>Approved Count: 4</li>
    </ul>
    <h3>Record Dates</h3>
    <p>11/18/2024</p>
    <h3>Job Numbers</h3>
    <p>S02375</p>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>Services: BN</li>
        <li>Management recommendations: F</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Corporate Structure (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>To approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our Common Stock from thirty (30) million shares to sixty (60) million shares (the &quot;Certificate Amendment Proposal&quot; or &quot;Proposal No. 2&quot;). <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 722199 (14.0%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 744641 (14.5%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 1902 (0.0%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 3675845 (71.5%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>CROWN ELECTROKINETICS CORP.</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: BN</li>
        <li>Management Recommendations: F</li>
        <li>Total Proposals: 2</li>
        <li>Range of Approval Rate of Failed Proposals: 38.7%</li>
        <li>Rejected Count: 1</li>
        <li>Approved Count: 1</li>
    </ul>
    <h3>Record Dates</h3>
    <p>12/16/2024</p>
    <h3>Job Numbers</h3>
    <p>S04340</p>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>Services: BN</li>
        <li>Management recommendations: F</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Corporate Structure (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>To approve a reverse stock split of our common stock at a ratio of not more than 1-for-200, such ratio to be determined by the Board of Directors on or prior to December 31, 2025, in its sole discretion. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 2368264 (6.3%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 3746308 (10.0%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 23709 (0.1%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 31260920 (83.6%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>NAUTICUS ROBOTICS, INC.</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: N/A</li>
        <li>Management Recommendations: N/A</li>
        <li>Total Proposals: 4</li>
        <li>Range of Approval Rate of Failed Proposals: 49.1%</li>
        <li>Rejected Count: 1</li>
        <li>Approved Count: 3</li>
    </ul>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>No services found for this issuer</li>
        <li>No management recommendations found for this issuer</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Corporate Structure (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>To approve an amendment to our Second Amended and Restated Certificate of Incorporation. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 154674 (4.3%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 160034 (4.4%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 33038 (0.9%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 3265644 (90.4%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>NANOVIBRONIX, INC.</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: BN</li>
        <li>Management Recommendations: F</li>
        <li>Total Proposals: 3</li>
        <li>Range of Approval Rate of Failed Proposals: 46.4%</li>
        <li>Rejected Count: 1</li>
        <li>Approved Count: 2</li>
    </ul>
    <h3>Record Dates</h3>
    <p>1/17/2025</p>
    <h3>Job Numbers</h3>
    <p>S08140</p>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>Services: BN</li>
        <li>Management recommendations: F</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Corporate Actions (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>Approval of an amendment to the Company&#x27;s Amended and Restated Certificate of Incorporation, as amended, to effect, at the discretion of the Company&#x27;s Board of Directors but prior to the one-year anniversary of the date on which the reverse stock split is approved by the Company&#x27;s stockholders at the Special Meeting, a reverse stock split of all of the outstanding shares of the Company&#x27;s common st... <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 307266 (7.3%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 355210 (8.5%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 6259 (0.1%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 3523056 (84.0%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>ZYVERSA THERAPEUTICS, INC.</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: N/A</li>
        <li>Management Recommendations: N/A</li>
        <li>Total Proposals: 1</li>
        <li>Range of Approval Rate of Failed Proposals: 49.9%</li>
        <li>Rejected Count: 1</li>
        <li>Approved Count: 0</li>
    </ul>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>No services found for this issuer</li>
        <li>No management recommendations found for this issuer</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Shareholder Equity (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>The approval of the issuance of up to an aggregate of 1,637,000 shares of the Company&#x27;s common stock issuable upon the exercise of certain warrants to purchase the Company&#x27;s common stock, in accordance with Nasdaq Listing Rule 5635(d). <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 118096 (6.1%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 118534 (6.1%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 2688 (0.1%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 1690446 (87.6%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>XWELL, INC.</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: BN</li>
        <li>Management Recommendations: F</li>
        <li>Total Proposals: 5</li>
        <li>Range of Approval Rate of Failed Proposals: 42.1%</li>
        <li>Rejected Count: 1</li>
        <li>Approved Count: 4</li>
    </ul>
    <h3>Record Dates</h3>
    <p>2/14/2025</p>
    <h3>Job Numbers</h3>
    <p>S09917</p>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>Services: BN</li>
        <li>Management recommendations: F</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Shareholder Equity (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>To approve an amendment to the XWELL, Inc. 2020 Equity Incentive Plan (as amended, the &quot;2020 Plan&quot;) to (i) increase the aggregate number of shares of Common Stock reserved for issuance under the 2020 Plan by 2,500,000 shares to a total of 3,125,000 shares and (ii) increase the maximum number of shares of Common Stock subject to awards granted during a single fiscal year to any director who is not ... <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 424126 (12.3%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 582596 (17.0%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 964 (0.0%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 2428455 (70.7%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>LIBERTY ENERGY INC.</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: BN</li>
        <li>Management Recommendations: F</li>
        <li>Total Proposals: 10</li>
        <li>Range of Approval Rate of Failed Proposals: 26.2%</li>
        <li>Rejected Count: 1</li>
        <li>Approved Count: 9</li>
    </ul>
    <h3>Record Dates</h3>
    <p>2/19/2025</p>
    <h3>Job Numbers</h3>
    <p>P25793</p>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>Services: BN</li>
        <li>Management recommendations: F</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Corporate Governance (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>Approve an amendment to the Company&#x27;s certificate of incorporation to delete the waiver of Section 203 of the Delaware General Corporation Law. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 37009544 (22.6%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 104335579 (63.8%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 360601 (0.2%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 21726473 (13.3%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>TEXAS CAPITAL BANCSHARES, INC.</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: BN</li>
        <li>Management Recommendations: F</li>
        <li>Total Proposals: 16</li>
        <li>Range of Approval Rate of Failed Proposals: 47.0%</li>
        <li>Rejected Count: 1</li>
        <li>Approved Count: 15</li>
    </ul>
    <h3>Record Dates</h3>
    <p>2/19/2025</p>
    <h3>Job Numbers</h3>
    <p>P24569</p>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>Services: BN</li>
        <li>Management recommendations: F</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Compensation (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>To approve, on an advisory basis, the 2024 compensation of the Company&#x27;s named executive officers as described in the Proxy Statement; <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 19322360 (42.3%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 21790400 (47.7%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 287122 (0.6%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 4257655 (9.3%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>ADITXT, INC.</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: BN</li>
        <li>Management Recommendations: F</li>
        <li>Total Proposals: 5</li>
        <li>Range of Approval Rate of Failed Proposals: 44.9%</li>
        <li>Rejected Count: 1</li>
        <li>Approved Count: 4</li>
    </ul>
    <h3>Record Dates</h3>
    <p>1/23/2025</p>
    <h3>Job Numbers</h3>
    <p>Z89366</p>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>Services: BN</li>
        <li>Management recommendations: F</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Corporate Actions (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>To grant discretionary authority to our BOD to (i) amend our certificate of incorporation to combine outstanding shares of our common stock into a lesser number of outstanding shares, or a &quot;reverse stock split,&quot; at a specific ratio within a range of one-for-five (1:5) to a maximum of a one-for-two hundred fifty (1:250) split, with the exact ratio to be determined by our BOD in its sole discretion;... <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 3247918 (7.2%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 3988690 (8.9%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 155730 (0.3%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 37433481 (83.5%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>LIBERTY TRIPADVISOR HOLDINGS, INC.</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: BN</li>
        <li>Management Recommendations: F</li>
        <li>Total Proposals: 4</li>
        <li>Range of Approval Rate of Failed Proposals: 35.5%</li>
        <li>Rejected Count: 1</li>
        <li>Approved Count: 3</li>
    </ul>
    <h3>Record Dates</h3>
    <p>3/21/2025</p>
    <h3>Job Numbers</h3>
    <p>S12443</p>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>Services: BN</li>
        <li>Management recommendations: F</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Compensation (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>A proposal to approve, on an advisory (nonbinding) basis, the compensation that may be paid or become payable to Liberty TripAdvisor&#x27;s named executive officers that is based on or related to the merger agreement and the transactions contemplated thereby. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 12574795 (18.3%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 22813702 (33.2%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 9986829 (14.5%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 23399527 (34.0%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>AIM IMMUNOTECH INC.</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: BN</li>
        <li>Management Recommendations: F</li>
        <li>Total Proposals: 1</li>
        <li>Range of Approval Rate of Failed Proposals: 47.4%</li>
        <li>Rejected Count: 1</li>
        <li>Approved Count: 0</li>
    </ul>
    <h3>Record Dates</h3>
    <p>3/25/2025</p>
    <h3>Job Numbers</h3>
    <p>S12000</p>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>Services: BN</li>
        <li>Management recommendations: F</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Corporate Actions (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>To approve a series of alternate amendments to our Certificate of Incorporation to effect, at the option of our Board of Directors, a reverse stock split of our outstanding common stock at a ratio of up to 1-for-100, such ratio to be determined by our Board of Directors in its sole discretion. We refer to this proposal as the &quot;Reverse Stock Split Proposal&quot; or &quot;Proposal 1.&quot; <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 11371860 (18.5%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 12609750 (20.5%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 79222 (0.1%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 37404778 (60.9%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>MOLINA HEALTHCARE, INC.</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: BD</li>
        <li>Management Recommendations: F</li>
        <li>Total Proposals: 13</li>
        <li>Range of Approval Rate of Failed Proposals: 40.6%</li>
        <li>Rejected Count: 1</li>
        <li>Approved Count: 12</li>
    </ul>
    <h3>Record Dates</h3>
    <p>3/7/2025</p>
    <h3>Job Numbers</h3>
    <p>P24787</p>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>Services: BD</li>
        <li>Management recommendations: F</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Compensation (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>To consider and approve, on a non-binding, advisory basis, the compensation of our named executive officers. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 18255073 (36.0%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 26697229 (52.6%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 66477 (0.1%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 5727201 (11.3%)</span>]</span></li>
    </ul>

<hr>


<hr>


    <h2>THE HACKETT GROUP INC</h2>

    <h3>Statistics</h3>
    <ul>
        <li>Service Type: BN</li>
        <li>Management Recommendations: F</li>
        <li>Total Proposals: 6</li>
        <li>Range of Approval Rate of Failed Proposals: 42.6%</li>
        <li>Rejected Count: 1</li>
        <li>Approved Count: 5</li>
    </ul>
    <h3>Record Dates</h3>
    <p>3/14/2025</p>
    <h3>Job Numbers</h3>
    <p>P25285</p>
    <h3>Services & Management Recommendations</h3>
    <ul>
        <li>Services: BN</li>
        <li>Management recommendations: F</li>
    </ul>
    <h3>Rejected Proposals Breakdown</h3>
    <ul>
        <li>Category Summary: Compensation (1)</li>
    </ul>
    <h3>Rejected Proposals List</h3>
    <ul>
        <li>To approve, in an advisory vote, the Company&#x27;s executive compensation. <span>[<span style='color:#c00;font-weight:bold'>total_for_shares: 9528647 (35.9%)</span> | <span style='color:#c00;font-weight:bold'>total_agn_shares: 12828949 (48.4%)</span> | <span style='color:#c00;font-weight:bold'>total_abs_shares: 40390 (0.2%)</span> | <span style='color:#c00;font-weight:bold'>total_other_shares: 4120104 (15.5%)</span>]</span></li>
    </ul>

<hr>


<hr>

</body>
</html>